Lupkynis (voclosporin) - Aurinia Pharma, Otsuka
Lupus nephritis: Mechanisms of kidney damage (LUPUS-KCR 2023) - May 20, 2023 - Pres time: May 18, 2023; 04:00 PM - 04:30 PM; Location: Auditorium; "Treatment still relies on the use of immunosuppressive and cytotoxic drugs while the newly approved Benslysta and Voclosporin may offer minimal advantage...In the first, we find that CaMK4 expression is increased only in podocytes from people with LN whereas in the second, only IgG from people with active LN can upregulate CaMK4 in cultured podocytes. In summary, our work offers new insights in the interface between the autoimmune response and kidney resident cells through which kidney damage is eventually executed and two novel liquid kidney approaches." 
Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus • ARG1 • IL17A • IL2 • IL23A
https://www.lupus-kcr2023.org/program/02.html?dateIdx=&sch_txt=&searchLupusCate=0&searchKcrCate=0
 
George Tsokos
 
May 20, 2023
 
Prev Next